Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C I Edvard Smith

Showing results (1-10 of 186) with videos related to

Pageof 19
Sort By:
Seminars in Cancer Biology|November 21, 2016
Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC)C I Edvard Smith
EMBO Reports|June 8, 2002
Disease models for every field: workshop on the molecular basis of human congenital lymphocyte disordersC I Edvard Smith
Leukemia & Lymphoma|June 12, 2025
Resistance to BTK inhibitors in leukemia: cysteine 481 in BTK equals cysteine 515 in the BTK isomer BTK-CC I Edvard Smith
The FEBS Journal|April 27, 2011
Tec family kinasesLiang Yu, C I Edvard Smith
Annual Review of Pharmacology and Toxicology|October 5, 2018
Therapeutic Oligonucleotides: State of the ArtC I Edvard Smith, Rula Zain
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 18, 2019
Targeted Oligonucleotides for Treating Neurodegenerative Tandem Repeat DiseasesRula Zain, C I Edvard Smith
Expert Opinion on Biological Therapy|August 29, 2003
Gene therapy of monogenic and cardiovascular disordersPontus Blomberg, C I Edvard Smith
Lakartidningen|June 8, 2021
[Gene therapy now enters many clinical disciplines]C I Edvard Smith, Pontus Blomberg
European Journal of Haematology|March 26, 2024
Reduced clone size upon BTK inhibitor resistance mutations relates to toxicity caused by inherited PLCG2 gain-of-function variationsC I Edvard Smith, Rula Zain
Frontiers in Immunology|June 28, 2021
Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling PathwayC I Edvard Smith, Jan A Burger
Pageof 19

Showing results (1-10 of 186) with videos related to

Sort By:
Pageof 19
Seminars in Cancer Biology|November 21, 2016
Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC)C I Edvard Smith
EMBO Reports|June 8, 2002
Disease models for every field: workshop on the molecular basis of human congenital lymphocyte disordersC I Edvard Smith
Leukemia & Lymphoma|June 12, 2025
Resistance to BTK inhibitors in leukemia: cysteine 481 in BTK equals cysteine 515 in the BTK isomer BTK-CC I Edvard Smith
The FEBS Journal|April 27, 2011
Tec family kinasesLiang Yu, C I Edvard Smith
Annual Review of Pharmacology and Toxicology|October 5, 2018
Therapeutic Oligonucleotides: State of the ArtC I Edvard Smith, Rula Zain
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 18, 2019
Targeted Oligonucleotides for Treating Neurodegenerative Tandem Repeat DiseasesRula Zain, C I Edvard Smith
Expert Opinion on Biological Therapy|August 29, 2003
Gene therapy of monogenic and cardiovascular disordersPontus Blomberg, C I Edvard Smith
Lakartidningen|June 8, 2021
[Gene therapy now enters many clinical disciplines]C I Edvard Smith, Pontus Blomberg
European Journal of Haematology|March 26, 2024
Reduced clone size upon BTK inhibitor resistance mutations relates to toxicity caused by inherited PLCG2 gain-of-function variationsC I Edvard Smith, Rula Zain
Frontiers in Immunology|June 28, 2021
Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling PathwayC I Edvard Smith, Jan A Burger
Pageof 19